A new study published today in Stem Cell Reports demonstrates how a human stem cell-derived model of the intestine can be used to identify potential therapies for inflammatory bowel disease (IBD), highlighting glycyrrhizin as a promising candidate for reducing intestinal inflammation and cell death.